SCHEMBL22609347

SCHEMBL22609347

COC(=O)c1noc(C)c1I

nearest known ligand 0.45

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.45
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 4/20 0.40
MAPT P10636 2/20 0.39
MEN1 O00255 2/20 0.39
USP2 O75604 1/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ATAD2 Q6PL18 1/20 0.37
POLB P06746 2/20 0.36
GPX4 P36969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL436752 0.81 ALDH1A1 (0.48) ALDH1A1
SCHEMBL25985564 0.80 NPSR1 (0.48) NPSR1KMT2AALDH1A1MAPTMEN1
SCHEMBL9585593 0.78 ALDH1A1 (0.50) NPSR1KMT2AALDH1A1MEN1USP2
SCHEMBL22609288 0.78 GRIA1 (0.46) KMT2AALDH1A1MEN1GPX4
SCHEMBL15248892 0.78 BRD4 (0.41) KMT2AALDH1A1ALOX15HSD17B10POLB
SCHEMBL31226160 0.77 NPSR1 (0.45) NPSR1KMT2AALDH1A1MAPTMEN1
SCHEMBL19893057 0.77 NPSR1 (0.45) NPSR1KMT2AALDH1A1MAPTMEN1
SCHEMBL31226129 0.77 ALDH1A1 (0.45) NPSR1KMT2AALDH1A1MAPTMEN1
SCHEMBL5431807 0.77 NPSR1 (0.45) NPSR1KMT2AALDH1A1MAPTMEN1
SCHEMBL4777369 0.76 ALDH1A1 (0.51) NPSR1KMT2AALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4252755-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2025-05-14 EP disclosed
US-20250084075-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2025-03-13 US disclosed
CN-119569706-A Therapeutic compounds 希四克斯探索有限公司 2025-03-07 CN disclosed
CN-112996785-B Therapeutic compounds 希四克斯探索有限公司 2024-12-06 CN disclosed
US-12098148-B2 Therapeutic compounds C4X DISCOVERY LIMITED (GB) 2024-09-24 US disclosed
EP-4252755-A2 THERAPEUTIC COMPOUNDS C4x Discovery Limited (GB) 2023-10-04 EP disclosed
EP-4252755-A2 THERAPEUTIC COMPOUNDS C4x Discovery Limited (GB) 2023-10-04 EP disclosed
EP-3870578-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2023-08-16 EP disclosed
EP-3870578-B1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LTD (GB) 2023-08-16 EP disclosed
US-20220002286-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2022-01-06 US disclosed
US-20220002286-A1 THERAPEUTIC COMPOUNDS C4X DISCOVERY LIMITED (GB) 2022-01-06 US disclosed
CN-112996785-A Therapeutic compounds 希四克斯探索有限公司 2021-06-18 CN disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002286-A1 THERAPEUTIC COMPOUNDS NFE2L2, KEAP1, NQO1 NPSR1 2304/4885KMT2A 3198/4885ALDH1A1 307/4885
US-12098148-B2 Therapeutic compounds NFE2L2, KEAP1, NQO1 NPSR1 2304/4885KMT2A 3198/4885ALDH1A1 307/4885
US-20250084075-A1 THERAPEUTIC COMPOUNDS NFE2L2, KEAP1, NQO1 NPSR1 2304/4885KMT2A 3198/4885ALDH1A1 307/4885
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS NPSR1 3687/4885KMT2A 3407/4885ALDH1A1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.